

Ref: ADL/SE/2024-25/11
May 3, 2024

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Compliance of Regulation 33 and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sub: Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2024 and Outcome of the Meeting of Board of Directors held on May 3, 2024.

This is to inform you that the Board of Directors of the Company at its Meeting held on **Friday, May 3, 2024**, has inter-alia, considered and approved the following:

- A) The Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended March 31, 2024, in this regards we enclose:-
- Statement showing the Financial Results (Standalone and Consolidated),
 - Statement of Assets and Liabilities (Standalone and Consolidated),
 - Cash Flow Statement (Standalone and Consolidated),
 - Auditor's Report on the Financial Results (Standalone and Consolidated),
 - Declaration in respect of Audit reports with un-modified opinion for the Financial Year ended March 31, 2024.
- B) Re-appointment of M/s GMVP & Associates LLP, Cost Accountant (Firm Registration No. 000910) as the Cost Auditor of the Company for the financial year ending March 31,2025. The required details pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed herewith in **Annexure - A**.

Further, please note that the Company has already made necessary arrangement to publish the financial results in the Newspapers as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

The Meeting of the Board of Directors commenced at 12:00 Noon and concluded at 4:15 P.M.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY
ICSI M. No.: F12932



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Annexure – A

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

Sr. No.	Particulars	Disclosure
1.	Name of Cost Auditor	M/s GMVP & Associates LLP, Cost Accountant (Firm Registration No. 000910)
2.	Reason for change	Re-appointment as the Cost Auditor of the Company.
3.	Date & Term of re-appointment	M/s GMVP & Associates LLP, Cost Accountant (Firm Registration No. 000910) re-appointed as the Cost Auditor of the Company on May 3, 2024 for a term of 1 (one) year for the Financial Year 2024-25.
4.	Brief Profile	M/s GMVP & Associates LLP is a Mumbai based firm. They have been present in the field of Costing, Finance & Accounts for past 35 Years.

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY
ICSI M. No.: F12932



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED						
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31st Mar' 2024						
(Rs. in lakhs except for share data)						
Sr. No.	Particulars	Standalone				
		Quarter Ended			Year Ended	
		31st Mar 2024 (Audited)	31st Dec 2023 (Audited)	31st Mar 2023 (Audited)	31st Mar 2024 (Audited)	31st Mar 2023 (Audited)
I	Revenue from operations	55,953	53,821	69,641	2,26,691	2,49,797
II	Other income	111	168	93	418	223
III	Total Income (I + II)	56,064	53,989	69,734	2,27,109	2,50,020
IV	Expenses :					
	(a) Cost of materials consumed	34,565	32,993	43,539	1,46,657	1,70,244
	(b) Purchase of stock-in-trade	1,091	564	743	3,586	4,701
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,450	2,817	4,467	2,677	(672)
	(d) Employee benefits expense	1,994	2,027	2,110	8,098	7,505
	(e) Finance costs	809	675	835	3,016	3,253
	(f) Depreciation and amortisation expense	1,234	1,180	1,168	4,767	4,729
	(g) Other expenses	9,948	9,446	9,930	39,059	39,778
	Total expenses (IV)	51,090	49,702	62,792	2,07,861	2,29,539
V	Profit before exceptional items and tax (III - IV)	4,974	4,287	6,942	19,248	20,481
VI	Exceptional items	-	-	-	-	-
VII	Profit before tax (V - VI)	4,974	4,287	6,942	19,248	20,481
VIII	Tax Expenses :					
	Provision for taxation - Current	1,510	1,075	1,775	4,960	5,325
	- Earlier year	-	-	-	-	-
	Provision for deferred taxation	(150)	50	(150)	100	(125)
	Total tax expenses (VIII)	1,360	1,125	1,625	5,060	5,200
IX	Profit / (Loss) for the Year (VII - VIII)	3,614	3,162	5,317	14,188	15,281
X	Other Comprehensive Income					
	Item that will not be reclassified to statement of Profit and Loss					
	Fair value changes on Investments, net	117	-	(54)	117	(54)
	Remeasurement of defined benefit Liability/Assets, net	21	-	(87)	21	(87)
	Foreign currency translation reserve	-	-	-	-	-
	Total Other Comprehensive Income, net	139	-	(142)	139	(142)
XI	Total Comprehensive Income for the Year (IX+X)	3,753	3,162	5,175	14,327	15,139
XII	Weighted average number of equity shares used for computing earning per share (face value of Rs.10 each)	9,194	9,194	9,260	9,194	9,260
	Profit attributable to :					
	Owner of the Company	3,614	3,162	5,317	14,188	15,281
	Non- Controlling Interest	-	-	-	-	-
	Total Comprehensive Income attributable to :					
	Owner of the Company	3,753	3,162	5,175	14,327	15,139
	Non- Controlling Interest	-	-	-	-	-
XIII	Earning per equity share (in Rs.) (not annualised)					
	(1) Basic	3.93	3.44	5.74	15.35	16.50
	(2) Diluted	3.93	3.44	5.74	15.35	16.50

Place: Mumbai
Date: 3rd May' 2024



For AARTI DRUGS LIMITED

Prakash M. Patil
(Chairman, Managing Director&CEO)
DIN : 00005618



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel . : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED						
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31st Mar' 2024						
(Rs. in lakhs except for share data)						
Sr. No.	Particulars	Consolidated				
		Quarter Ended		Year Ended		
		31st Mar 2024 (Audited)	31st Dec 2023 (Audited)	31st Mar 2023 (Audited)	31st Mar 2024 (Audited)	31st Mar 2023 (Audited)
I	Revenue from operations	61,999	60,594	74,241	2,52,858	2,71,605
II	Other income	108	167	87	403	219
III	Total Income (I + II)	62,107	60,761	74,328	2,53,261	2,71,825
IV	Expenses :					
	(a) Cost of materials consumed	36,664	40,107	44,640	1,57,198	1,76,897
	(b) Purchase of stock-in-trade	2,033	(2,170)	2,164	8,023	12,129
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,013	2,587	4,747	2,551	(175)
	(d) Employee benefits expense	2,587	2,559	2,546	10,234	9,208
	(e) Finance costs	913	760	863	3,352	3,329
	(f) Depreciation and amortisation expense	1,358	1,266	1,250	5,145	5,032
	(g) Other expenses	11,121	10,498	10,788	43,206	42,986
	Total expenses (IV)	55,689	55,606	67,000	2,29,708	2,49,407
V	Profit before exceptional items and tax (III - IV)	6,418	5,155	7,328	23,553	22,418
VI	Exceptional items	-	-	-	-	-
VII	Profit before tax (V - VI)	6,418	5,155	7,328	23,553	22,418
VIII	Tax Expenses :					
	Provision for taxation - Current	1,510	1,427	1,889	5,956	5,886
	- Earlier year	-	-	-	-	-
	Provision for deferred taxation	177	57	(179)	437	(103)
	Total tax expenses (VIII)	1,687	1,484	1,710	6,394	5,782
IX	Profit / (Loss) for the Year (VII - VIII)	4,731	3,671	5,618	17,159	16,636
X	Other Comprehensive Income					
	Item that will not be reclassified to statement of Profit and Loss					
	Fair value changes on Investments, net	117	-	(54)	117	(54)
	Remeasurement of defined benefit Liability/Assets, net	17	-	(95)	17	(95)
	Foreign currency translation reserve	(128)	-	-	(128)	-
	Total Other Comprehensive Income, net	6	-	(150)	6	(150)
XI	Total Comprehensive Income for the Year (IX+X)	4,737	3,671	5,468	17,165	16,486
XII	Weighted average number of equity shares used for computing earning per share (face value of Rs.10 each)	9,194	9,194	9,260	9,194	9,260
	Profit attributable to :					
	Owner of the Company	4,737	3,667	5,609	17,142	16,631
	Non- Controlling Interest	-6.19	3.92	8.83	17.25	4.84
	Total Comprehensive Income attributable to :					
	Owner of the Company	4,744	3,667	5,459	17,154	16,481
	Non- Controlling Interest	-6.19	3.92	8.83	10.85	4.84
XIII	Earning per equity share (in Rs.) (not annualised)					
	(1) Basic	5.15	3.99	6.07	18.56	17.97
	(2) Diluted	5.15	3.99	6.07	18.56	17.97

Place: Mumbai
Date: 3rd May' 2024



For AARTI DRUGS LIMITED

Prakash M. Patil
(Chairman, Managing Director & CEO)
DIN : 00005618



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED					
STATEMENT OF ASSETS AND LIABILITIES AS AT 31st Mar' 2024					
Particulars	Standalone		(Rs. in lakhs)		
	31st Mar 2024	31st Mar 2023	31st Mar 2024	31st Mar 2023	
ASSETS					
1 Non - Current Assets					
Property, Plant and Equipment	72,033	63,199	80,816	67,325	
Right of use Assets	175	219	175	219	
Capital work - in - progress	22,162	16,075	22,523	18,681	
Intangible assets	21	31	118	79	
Intangible assets under development	-	-	3,565	2,354	
Financial Assets					
Investments	2,997	2,862	1,997	1,880	
Other Non- Current Assets	1,671	2,211	1,970	2,423	
Total Non- Current Assets	99,060	84,596	1,11,164	92,961	
2 Current Assets					
Inventories	44,177	47,773	48,589	51,629	
Financial Assets					
(i) Trade receivable	64,395	80,168	70,455	86,484	
(ii) Cash and cash equivalents	272	152	674	750	
(iii) Other Bank Balances	110	116	269	146	
(iv) Current Loan	19	28	24	32	
(v) Other Current Financial Assets	1,132	1,203	1,134	1,203	
Other current assets	7,997	5,515	10,927	8,935	
Total Current Assets	1,18,102	1,34,953	1,32,072	1,49,179	
Non current Asset held for sale	-	-	-	-	
TOTAL ASSETS	2,17,162	2,19,550	2,43,236	2,42,140	
EQUITY AND LIABILITIES					
1 EQUITY					
Share Capital	9,194	9,260	9,194	9,260	
Other Equity	1,08,327	1,02,170	1,18,961	1,09,983	
Total Equity Attributable to Equity Holders of the Company	1,17,521	1,11,430	1,28,155	1,19,243	
Non- Controlling Interests	-	-	40.58	23.33	
Total Equity	1,17,521	1,11,430	1,28,195	1,19,267	
LIABILITIES					
2 Non-current liabilities					
Financial Liabilities					
(i) Borrowings	23,826	16,189	27,533	20,468	
(ii) Lease Liability	91	40	91	40	
(iii) Other financial liability	17	17	17	17	
Provisions	274	298	274	303	
Deferred tax liabilities (Net)	6,973	6,837	7,571	7,097	
Total of Non current liabilities	31,181	23,380	35,486	27,925	
3 Current liabilities					
Financial Liabilities					
(i) Borrowings	23,460	37,120	28,709	40,184	
(ii) Lease Liability	95	199	95	199	
(iii) Other Financial Liabilities	2,556	1,397	2,633	1,397	
(iv) Trade payables					
Dues of micro enterprises and small enterprises	2,446	1,362	2,944	2,078	
Dues of creditors other micro enterprises and small enterprises	36,883	40,540	39,605	45,948	
Provisions	153	263	295	437	
Other current liabilities	2,617	3,446	5,156	4,280	
Current Tax Liabilities (Net)	250	413	118	423	
Total of current liabilities	68,460	84,739	79,554	94,948	
TOTAL EQUITY AND LIABILITIES	2,17,162	2,19,550	2,43,236	2,42,140	

Notes :

- The above results for the quarter and year ended 31st March, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 3rd May, 2024.
- The company has completed buyback of 6,65,000 equity shares of face value Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding transaction costs such as brokerage, Buyback tax, securities transaction tax, goods and service tax, stamp duty etc.) ("Buyback Size") on 24th August, 2023. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,93,50,000 divided into 9,19,35,000 Equity Shares of Rs.10/- each.
- Company has only one business segment i.e. pharmaceuticals.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

Place: Mumbai
Date: 3rd May 2024



For AARTI DRUGS LIMITED

Prakash M. Patil
(Chairman, Managing Director&CEO)
DIN : 00005618



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED					
CASH FLOW STATEMENT AS AT 31st Mar' 2024 (Rs. in lakhs)					
S.No	Particulars	Standalone		Consolidated	
		31st Mar 2024	31st Mar 2023	31st Mar 2024	31st Mar 2023
A.	Cash Flow from Operating Activities				
	Net Profit before Tax and Exceptional Items	19,248	20,481	23,553	22,418
	ADJUSTMENT FOR:				
	Depreciation & Amortisation	4,767	4,729	5,145	5,032
	Provision for Doubtful debts /Bad debts	147	-	190	76
	Unrealised Foreign Exchange (Gain)/Loss (Net)	49	(61)	(183)	(131)
	Interest Paid	3,016	3,253	3,352	3,619
	Interest Received	(240)	(67)	(250)	(70)
	Dividend Received	(0)	(0)	(0)	(0)
	Investment W/off	29	-	29	-
	Profit on Sale of Assets	-	(11)	18	(11)
	Operating Profit before Working Capital Changes	27,017	28,324	31,854	30,933
	Trade & Other Receivable	13,229	(8,705)	16,107	(9,442)
	Changes in Inventories	3,596	1,074	3,425	582
	Trade & Other Payable	(5,008)	960	(9,253)	(2,774)
	Cash generated from operation	38,834	21,653	42,132	19,300
	Direct Taxes Paid	(5,123)	(5,483)	(6,240)	(5,967)
	Net Cash Flow from Operating Activities	33,710	16,170	35,892	13,332
B.	Cash Flow from Investing Activities				
	Purchase of Fixed Assets / Capital Work in Progress/ Advances/R&D	(18,932)	(13,054)	(22,633)	(16,467)
	Sale of PPE	-	-	19	-
	Investments	(17)	(127)	0	(0)
	Interest Received	240	67	250	70
	Dividend Received	0	0	0	0
	Net Cash Flow from Investing Activities	(18,709)	(13,114)	(22,365)	(16,397)
C.	Cash Flow from Financing Activities				
	Proceeds from Long Term Borrowings	14,250	9,322	14,819	11,584
	Repayment of Long Term Borrowings	(4,326)	(5,586)	(4,594)	(5,586)
	Proceeds/(Repayment) from Short Term Borrowings	(13,764)	(2,596)	(12,453)	140
	Capital Proceeds	-	-	-	76
	Buy Back of shares	(5,985)	-	(5,985)	-
	Buyback Tax	(1,332)	-	(1,332)	-
	Dividend Paid	(927)	(940)	(927)	(940)
	Interest Paid	(2,795)	(3,253)	(3,131)	(3,619)
	Net Cash Flow from Financing Activities	(14,881)	(3,054)	(13,603)	1,654
	Net Increase in Cash and Cash Equivalents (A+B+C)	120	3	(76)	(1,411)
	Opening Cash and Cash Equivalents	152	149	750	2,161
	Closing Cash and Cash Equivalents	272	152	674	750

Place: Mumbai
Date: 3rd May' 2024



For AARTI DRUGS LIMITED

Prakash M. Patil
(Chairman, Managing Director&CEO)
DIN : 00005618



Independent Auditors' Report on Audit of Standalone Financial Results

To Board of Directors of
Aarti Drugs Limited

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of Aarti Drugs Limited (“the Company”) for the quarter and year ended 31 March 2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

1. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
2. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India of the net profit and total other comprehensive income, and other financial information of the Company for quarter and year ended 31 March 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone financial results have been prepared on the basis of the standalone financial statements.

The Company’s Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design,





implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider





quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

Comparative Audited Standalone Financial Results

The comparative audited standalone financial results for the quarter and year ended 31 March 2023 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants, whose audit report dated 29 April 2023 had expressed an unmodified opinion on financial statements.

Our opinion is not modified in respect of above matters.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

Tejas Parikh
Partner
Membership No. 123215
UDIN: -24123215BKBNYR2593
Place: Mumbai
Date: 3 May 2024





Independent Auditors' Report on Audit of Consolidated Financial Results

To Board of Directors of Aarti Drugs Limited

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Drugs Limited (“Holding company”) and its subsidiaries (holding company and its subsidiaries together referred to as “the Group”) for the quarter and year ended 31 March 2024 (“the Statement”), being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries (refer other matter paras), the Statement:

1. includes the results of the following entities:
 - i. Pinnacle Life Science Private Limited
 - ii. Aarti Speciality Chemicals Limited
 - iii. Pinnacle Chile SpA.
2. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
3. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total other comprehensive income and other financial information of the Group for quarter and year ended 31 March 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matters” paragraph below, is sufficient and appropriate to provide a basis for our opinion.





Management's Responsibilities for the Consolidated Financial Results.

These consolidated financial results have been prepared on the basis of the consolidated financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement





resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial results.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.





Other Matters

I. Comparative Audited Consolidated Financial Results

The comparative audited consolidated annual financial results for the year ended 31 March 2023 were audited by erstwhile statutory auditors, Kirtane & Pandit, LLP (FRN: 105215W/W100057), Chartered Accountants whose annual auditors report dated F29 April 2023 had expressed an unmodified opinion on financial statements.

Our opinion is not modified in respect of above matter.

II. Financial Results of Subsidiaries not audited by us.

The consolidated financial results include the audited financial results of 1 foreign subsidiary whose annual financial Results/ financial information reflects total assets of Rs. 5,349.68 Lakhs as at 31 March 2024, and total revenues of Rs. 1,918.24 Lakhs and Rs. 7,616.77 Lakhs and total net profit after tax of Rs. 4.24 Lakhs and Rs. 345.00 Lakhs for the quarter and year ended 31 March 2024 respectively, and cash inflow (net) of Rs.88.18 lakhs for the year ended 31 March 2024 as considered in the consolidated financial results. These audited financial statements have been furnished to us by the board of directors and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such audited annual financial statement. In our opinion and according to the information and explanations given to us by the Board of Directors, these annual financial statements is not material to the Group.

Our opinion is not modified in respect of above matter.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

Tejas Parikh
Partner
Membership No. 123215
UDIN: -24123215BKBNYS7710
Date: 3 May 2024
Place: Mumbai



Ref: ADL/SE/2024-25/11
May 3, 2024

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sub: Declaration in respect of Audit Reports with un-modified opinion for the financial year ended March 31, 2024.

We hereby confirm and declare that the Statutory Auditors of the Company M/s. Gokhale & Sathe, Chartered Accountants (FRN: 103264W) have issued the Audit Report with un-modified opinion in respect of Annual Audited Standalone and Consolidated Financial Results for the Financial Year ended March 31, 2024.

Kindly take the same on record.
Thanking you,

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY
ICSI M. No.: F12932